版本:
中国

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

June 8 Alkermes PLC:

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

* All participants in double-blind portion of study will be eligible to continue in open-label safety study of ALKS 3831 for additional 24 months Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐